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Background: Lung cancer is one of the leading causes of cancer-related mortality worldwide. Conventional
chemotherapy and radiotherapy are the primary therapeutic methods for lung cancer with the use of combination
therapies gaining popularity. The frequency and duration of treatment, as well as, managing lung cancer by targeting
multiple aspects of cancer biology is often limited by toxicity to the patient. There are many naturally occurring anticancer
agents that have a high degree of efficacy and low toxicity, offering a viable and safe approach for the treatment of
lung cancer. The herbs traditionally used in Chinese medicine for anticancer treatment offer great potential to enhance
the efficacy of conventional therapy. In this study, we evaluated the synergistic effects of Fei-Liu-Ping (FLP) ointment in
treating lung cancer; a known anticancer Chinese herbal based formula.
Methods: In this study, A549 human lung carcinoma cell line and Lewis lung carcinoma xenograft mouse model were
used. In addition, we utilized an in vitro co-culture system to simulate the tumor microenvironment in order to evaluate
the molecular mechanisms of FLP treatment.
Results: FLP treatment significantly inhibited tumor growth in the Lewis lung xenograft by 40 percent, compared to
that of cyclophosphamide (CTX) of 62.02 percent. Moreover, combining FLP and CTX inhibited tumor growth by 83.23
percent. Upon evaluation, we found that FLP treatment reduced the concentration of serum pro-inflammatory
cytokines IL-6, TNF-α, and IL-1β. In addition, we also found an improvement in E-cadherin expression and inhibition
of N-cadherin and MMP9. We found similar findings in vitro when we co-cultured A549 cells with macrophages.
FLP treatment inhibited A549 cell growth, invasion and metastasis, in part, through the regulation of NF-κB and
altering the expression of E-cadherin, N-cadherin, MMP2 and MMP9.
Conclusions: FLP exerts anti-inflammatory properties in the tumor microenvironment, which may contribute to its
anticancer effects. FLP treatment may be a promising therapy for inflammation associated lung cancer treatment
alone, or in combination with conventional therapies and may prevent lung cancer metastasis.
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Lung cancer is the most commonly diagnosed malignancy
and the main cause of cancer-related deaths worldwide,
with an estimated 15 percent 5-yr survival rate [1,2].
While many advances in chemotherapy and radiotherapy
have been made, overall patient survival rate has remained
unchanged in recent years. During the early stages of lung
cancer, surgery is effective; however, the five-year sur-
vival rate is approximately 25 percent, which is attrib-
uted mostly to remission and metastasis [3]. Preventing
reoccurrence and metastasis is an important step in im-
proving the survival for lung cancer patients. Minimiz-
ing the severity of some side effects can improve the
success of therapeutic methods and improve patient
quality of life.
Traditional Chinese medicine has low toxicity accom-
panied with few side effects, and offers a promising ther-
apy for lung cancer patients [4,5]. Previous clinical and
epidemiological studies demonstrated the efficacy of Trad-
itional Chinese Medicine in treating lung cancer patients
[6]. Experimental studies show that traditional Chinese
medicine has multiple roles and targets in the treatment
of lung cancer patients [7,8]; however, the mechanisms
have yet to be elucidated.
Fei-Liu-Ping (FLP) ointment is an oral prescription
medication that is used to treat lung cancer patients in
China. FLP ointment has been shown to possess many
anticancer properties [9], including improving the ability
to stimulate dendritic cells [10], inhibiting VEGF [10]
and modulating MMP9 and TIMP-1 expression [9]. The
effects of FLP treatment on the tumor microenviron-
ment have yet to be investigated.
The tumor microenvironment is an area of immense
research; unlike normal cells, the microenvironment of
cancer cells is hypoxic, acidic, hypertensive, with a greater
number of growth factors secretion and proteolysis en-
zymes that promote proliferation and cell survival [11]. In
addition, the tumor microenvironment is in a chronic in-
flammatory state that has been shown to play a critical
role in tumor growth, progression, and metastasis [12].
In the clinic, we have found that FLP ointment relieves
the symptoms manifested in patients with lung cancer that
may be associated with inflammation. We hypothesized
that FLP ointment could alleviate inflammation within the
microenvironment; thus, preventing progression and me-
tastasis. In this study, we were able to show that FLP in-
hibits tumor growth in a Lewis lung cancer xenograft, and
inhibit migration, invasion and metastasis in A549 lung
cancer carcinoma cell lines under inflammatory conditions.
Methods
Materials
FLP ointment was supplied from Pharmaceutical prepar-
ation center of Guang’anmen Hospital, China Academy ofChinese Medical Sciences. (No.(98)JWY[058] DF-1657)
(Beijing, China). Cyclophosphamide (CTX) was supplied
by Shanxi Powerdone Pharmaceutics Co. (Shanxi, China).
Antibodies: NF-κB (p65), E-cadherin, N-cadherin, and
MMP9, were purchased from Abcam (Cambridge, MA,
USA). β-actin was purchased from Cell Signaling Tech-
nology (Danvers, MA, USA). ELISA kits for IL6, IL1β,
and TNF-α were purchased from R&D systems (Minneapolis,
MN, USA).
Preparation of FLP ointment
The herbs used in FLP ointment are the roots of Astragalus
membranaceus (Fisch.) Bge.var.mongholicus (Bge.) Hsiao
(Huang-Qi), Panax quinquefolium L. (Xi-Yang-Shen),
Ophiopogon japonicas (Thunb.) Ker-Gawl. (Mai-Dong),
Glehnia littoralis Fr. Schmidt ex Miq. (Bei-Sha-Shen),
Agrimonia pilosa Ledeb. (Xian-He-Cao), Polygonum
bistorta L. (Quan-Shen), Patrinia villosa (Thunb.) Juss.
(Bai-Jiang-Cao), Panax notoginseng (Burk.) F.H. Chen
(San-Qi), Fritillaria cirrhosa D. Don (Chuan-Bei-Mu),
Glycyrrhiza uralensis Fisch. (Gan-Cao), Cordycrps sinensis
(Berk.) Sacc. (Dong-Cong-Xia-Cao) and the fruits of Pru-
nus persica (L.) Batsch (Tao-Ren) and Prunus armeniaca
L. var ansu Maxim. (Xing-Ren). All those herbs were from
Guang’anmen Hospital according to the original propor-
tion, and decocted twice with 8-fold volume of distilled
water for 1 hour. The decoction were collected, filtered,
merged and concentrated to 2 g/mL (equivalent to crude
herb materials), and stored at 4°C for oral using.
Animal studies
All mouse experiments were agreed to and regulated by
the Ethical Committee of China Academy of Chinese
Medical Sciences. Pathogen free male C57BL/6 mice were
purchased from Vital River Company (Beijing, China) at
6-weeks of age and were maintained in a temperature-
and humidity-controlled animal facility with a 12-h light/
dark cycle. Animals were given free access to water and
are monitored closely for any clinical signs of poor health
throughout the study. All the animal experiments were
conducted in accordance with the guidelines of the Na-
tional Institutes of Health for the care and use of laboratory
animals. After one-week acclimation, mice were randomly
sorted into 5 treatment groups of 10 animals: Non-tumor-
bearing (NT), Vehicle control (PBS) Fei-Liu-Ping ointment
treated (FLP), cyclophosphamide treated (CTX), and
FLP + CTX treated. Xenografts were performed under
anesthesia by injecting 2 × 106 Lewis lung cancer cells
in 0.1 ml volume into the right flank of the mouse. The
following day, mice were treated according to group.
FLP mice were treated orally with 100 mg/kg FLP by
gavaging each day, for 21 days. CTX group mice were
given three IP injections of CTX at 60 mg/kg, on day 2,
7, and 14 following tumor injection. FLP + CTX group
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ments described above. The vehicle control group re-
ceived PBS gavaging each day, for 21 days. Mice were
euthanized by CO2 asphyxiation on day 21 and tumor
tissues were collected, measured and weighed. Serum
from each mouse was also collected into 1.5 ml sterilized
micro-tubes and kept on ice for 40 minutes, then centri-
fuged at 4°C at 3000 RPM for 15 minutes, and stored
at −80°C for further analysis.
Tumor inhibition rate
Tumor inhibition rate was calculated as follows: Tumor
inhibition rate = (1- average weight of tumors in treatment
group/average weight of tumors in control group) × 100%.
Immunohistochemistry
Paraffin embedded tumor tissue was sectioned at 5 μm,
onto glass microscope slides and subjected to immunohis-
tochemical analysis. Briefly, tissue sections were deparaffi-
nized in xylene and rehydrated in graded ethanol. Sections
were then subjected to antigen retrieval and blocked for
1 hour in normal serum. Sections were incubated in pri-
mary antibody solution at the following dilutions, NF-κB,
1:50; N-cadherin, 1:100; E-cadherin, 1:200; MMP9, 1:200,
overnight. This was followed by incubation in a horserad-
ish peroxidase (HRP)-conjugated secondary antibody (Cell
Signaling Technology) for 1 hour. Sections were visualized
with 3, 3’diaminobenzidine (DAB) (Millipore, Billerica,
MA, USA) and lightly counterstained with hematoxylin.
Expression of positive cells was performed using image
analysis software ImageProPlus 4.5 (Diagnostic Instru-
ments, USA).
Western blot analysis
Western blot analysis of protein isolated from tumor tis-
sue was performed as follows. Briefly, 100 mg tumor tissue
from each sample was homogenized in 1 ml radioimmu-
noprecipitation assay (RIPA) lysis buffer (Thermo scientific,
Waltham, MA, USA). Protein concentration was calculated
using standard bovine serum albumin (BSA) curve. Ap-
proximately 30 μg of protein was loaded and fractionated
by SDS-PAGE and transferred to PVDF membrane and
probed with the following primary antibodies at the in-
dicated dilution. NF-κB (1:1000), E-cadherin (1:1000),
N-cadherin (1:1000), MMP9 (1:500), and β-actin (1:5000)
followed by a horseradish peroxidase (HRP)-conjugated
secondary antibodies. Signal was visualized by adding ECL
detection reagent (Amersham Life Science, Piscataway,
NJ, USA).
Cell culture
A549 human adenoma cell line was obtained from cell
resource center of the Institute of Basic Medical Sci-
ences Chinese Academy of Medical Sciences. Cells werecultured in RPMI1640 with 10% FBS, 100U/ml penicillin
and 100 mg/ml streptomycin at 37°C in humidified air
with 5% CO2. THP-1 human monocyte cell line was ob-
tained from cell resource center of the Institute of Basic
Medical Sciences Chinese Academy of Medical Sciences
and cultured in RPMI1640 with 10% FBS at 37°C in hu-
midified air with 5% CO2.
To study the effects of Fei-Liu-Ping (FLP) ointment
in vitro that closely resembles the serum bioavailability
of FLP treatment in vivo, we utilized serum pharmacol-
ogy previously described in [13-16]. Briefly, Wistar rats,
a strain of albino laboratory rats that are often used to
study safety and efficacy testing, were subjected to saline,
FLP, or CTX treatment. Animals received either oral
gavage of saline treatment, or FLP treatment at a low,
medium or high dose (50, 100, 200 mg/kg, respectively),
or IP injections of CTX (30 mg/kg) twice a day for three
consecutive days. On the third day, serum was collected
from the animals, filtered through a 0.2 μm cellulose
acetate membrane. The serum collected was used for
the treatments in all downstream in vitro assays and
listed as follows; NRS (normal rat serum, saline treated),
FLPL (FLP low dose), FLPM (FLP medium dose), FLPH
(FLP high dose).In-vitro system of inflammatory microenvironment
THP-1 cells were seeded on 6-well plates at 1 × 106 cells/well.
The THP-1 monocyte cells were converted to macro-
phages using Phorbol 12-Myristate 13 acetate (PMA) pur-
chased from Sigma Aldrich (Shanghai, China) at a final
concentration of 320nM and incubated at 37°C with 5%
CO2 for 48 hours to allow for maximal conversion of the
THP-1 monocytes to THP-1 macrophages. All the experi-
ments were performed in polystyrene with Transwell in-
serts with a pore size of 0.4 μm from BD Biosciences (San
Diego, CA USA) using serum free medium. The co-
culture experiments consisted of adding an insert contain-
ing confluent THP-1 macrophages to cultured A549 cells
that are grown in the bottom compartment of the plate.
The THP-1 macrophages were never in direct contact
with the A549 cells. The cultures were exposed to either
vehicle control or various FLP treatments. Cultured A549
without the addition of THP-1 macrophages was used as
an experimental control. After 24 hours, the medium was
recovered and stored at −80°C for further analysis.ELISA detection of inflammatory cytokines
ELISA analysis was performed according to the manu-
facturers’ instructions and analyzed using a spectrom-
eter reading at an absorbance of 450 nm with 570 nm
used as the reference wavelength (Synogen4, Gene com-
pany Ltd).
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A549 cells were incubated in 96-well plates in the
presence of FLP or CTX treatments for 48 hours. MTT
(3-[4, 5-dimethylthiazol-2-yl]-2, 5 diphenyl tetrazolium
bromide) purchased from Sigma-Aldrich (Shanghai,
China) was added for 4 h at the final concentration of
0.5 mg/ml. Subsequently, the culture medium was re-
moved and after dissolving the formazan crystals in
DMSO, plates were read immediately at 570 nm using
an absorbance plate reader (Bio- Rad, CA, USA). Cell
survival was defined as the growth of treated cells com-
pared with untreated cells.Figure 1 Fei-Liu-Ping ointment inhibits the tumor growth. FLP effects
cells were injected into 6-week-old C57BL/6 mice (2 × 106 cells/mouse). FL
for 21 days. CTX group mice were given three IP injections of CTX at 60 m
mice were given a combination of CTX and FLP treatments described abov
displayed as mean of 10 mice in each group, +/− standard deviation. #P < 0.0
Inhibition rate calculated as percent compared to PBS control. (C) Representa
ELISA plotted as concentration for (D) TNF-α (E) IL-6 (F), IL-1β. Data displayed
**, P < 0.01 compared to PBS vehicle.Scratch wound assay
A549 cells were grown to confluence on a 24-well dish
in serum-free medium. A single stripe (500 μM wide) was
scraped on the cell-coated surface with a disposable plas-
tic pipette tip. Cells were treated with FLP or CTX and
incubated for 24 hours at 37°C with 5% CO2. Migration
was analyzed using light microscopy with Image-Pro
Plus Version 6.0.
Invasion assay
Cell invasion was determined using Matrigel invasion
chambers purchased from BD Biosciences (San Diego,on tumor growth in Lewis lung cancer xenograft. Lewis lung cancer
P mice were treated orally with 100 mg/kg FLP by gavaging each day,
g/kg, on day 2, 7, and 14 following tumor injection. FLP + CTX group
e. (A) Tumors were weighed (grams) at the end of 21 days. Data
5 compared to FLP + CTX; **, P < 0.01 compared to PBS control. (B) Tumor
tive photomicrographs of tumors. Serum cytokine analysis detected using
as mean of 10 separate samples in each group +/− Standard deviation.
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tions. Briefly, 1 × 104 A549 cells were seeded into the
upper chamber in serum free medium separated by a
permeable membrane. The bottom chamber contained
10% serum in the presence or absence of FLP or CTX.
Serum-free medium in the bottom chamber was used as
a control. After 24 hours the cells in the membrane was
fixed, stained and counted using light microscopy.
Immunofluorescent staining
After pre-treatment with FLP or CTX, A549 cells were
fixed for 20 minutes using 4% formaldehyde in PBS. The
cells were blocked in 1% bovine serum albumin with
0.02% Triton X-100 for 1 hour and then incubated withFigure 2 Fei-Liu-Ping ointment decreases NF-κB expression, N-Cadhe
in vivo. Effect of FLP on the expression of NF-κB, E-cadherin, N-cadherin an
was subjected to immunohistochemical analysis and stained for NF-κB, E-c
as representative photomicrographs from each group (n = 10) at original m
group, lysed and protein extracts were analyzed by Western blot for analys
Data analyzed using densitometry.primary antibodies, NF-κB (p65) (1:200), E-cadherin (1:200),
N-cadherin (1:200), MMP9 (1:100), MMP2 (1:100),
overnight at 4°C followed by a 1 hour incubation in Alex
Fluor594 secondary antibody (1:400) and counterstained
with DAPI. Molecular DevicesMetaXpress® Image Ac-
quisition and Analysis Software were used for analysis
of translocation of NF-κB p65, E-cadherin, N-cadherin,
MMP2 and MMP9.
Statistical analysis
All data is presented as the mean ± standard deviation.
The significance of the difference between groups was
evaluated by one-way repeated-measures analysis of vari-
ance (ANOVA) and multiple comparisons with Prism 5.0rin, and MMP9 expression and increases expression of E-Cadherin
d MMP9. (A) Tumor tissue was collected from Lewis Lung xenograft
adherin, N-cadherin, and MMP9 antibody, respectively. Data is shown
agnification × 100. (B) Tumor tissue was collected from 10 mice per
is for NF-κB, E-cadherin and MMP9. A representative blot is shown.
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where appropriate. P < 0.05 were considered to be statisti-
cally significant.
Results
FLP treatment inhibits tumor growth in Lewis lung cancer
xenograft mice
To measure tumor growth inhibition caused by FLP oint-
ment treatment Lewis lung cancer xenograft mice were
treated with PBS, FLP ointment, CTX or a combination of
FLP ointment and CTX. At the end of the study, the mice
were euthanized and tumor tissues were measured and
weighed. Figure 1A shows that FLP ointment inhibited theFigure 3 FLP inhibits A549 cell proliferation and migration in vitro. Ef
seeded in 96-well plates and treated with NRS (vehicle control), FLP treatm
assay. Data are shown as mean ± standard error for three independent exp
THP-1 macrophages for 24 hours and treated with FLP at different dosages and s
of three independent experiments are shown and quantitated using imagingtumor growth compared with PBS vehicle group (p < 0.01).
CTX could also significantly inhibit the tumor growth
compared with PBS vehicle group (p < 0.01). FLP oint-
ment combined with CTX was more effective in reducing
the tumor growth compared with FLP ointment alone, or
CTX alone. As shown in Figure 1B and C, FLP inhibition
rate was 40 percent compared with PBS vehicle group;
CTX inhibition rate was 64.02 percent compared with
PBS vehicle group; the inhibition rate for FLP combined
with CTX was 83.23 percent. From the above results, we
found FLP ointment could inhibit the tumor growth of
Lewis lung cancer, by itself or when combined with other
conventional chemotherapeutic agent, CTX.fect of FLP on cellular proliferation and migration. (A) A549 cells were
ent (low, medium, high) or CTX for 48 hours and subjected to MTT
eriments. *P < 0.05 versus NRS. (B) A549 cells were co-cultured with
ubjected to scratch-wound healing assay. Representative photomicrographs
software measured as pixels (C). *P < 0.05 versus NRS.
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cytokines expression in serum of Lewis lung cancer
xenograft mice
FLP ointment was first prescribed in the clinic to lung
cancer patients to relieve symptoms associated with in-
flammation, such as, cough, phlegm, and blood in the
phlegm. Deregulation of inflammatory cytokines has been
previously found to be associated with the above symp-
toms [17-20]. Serum collected from euthanized mice was
analyzed for pro-inflammatory cytokines using ELISA. We
found minimal detection of pro-inflammatory cytokines in
the serum of the NT group (normal mice without tumor),
whereas, tumor bearing mice had significantly elevated
levels of TNF-α, IL-6 and IL-1β (Figure 1D, E and F).
Interestingly, treatment with FLP decreased these cyto-
kines to similar levels seen in normal mice withoutFigure 4 FLP inhibits A549 cells invasion and inhibits pro-inflammato
FLP on A549 cell invasion and pro-inflammatory cytokines TNF-α, IL-1β and
invasion assay treated with NRS (Vehicle control), FLP (low, medium high) o
to calculate migrated cells for each treatment, 5 fields were randomly chos
times. *P < 0.05 vs. NRS group. Measurements for pro-inflammatory cytokin
(D) IL-1β and (E) IL-6 in the supernatant. *P < 0.05 vs. A549 + NRS group.tumors. While a similar decrease in TNF-α and IL-1β was
seen in the CTX treated mice, FLP treatment decreased
IL-6 levels to a greater degree compared to that of the
CTX treatment. Our results suggest that inflammation
is induced by the tumor in Lewis lung cancer xenograft
mice and FLP treatment could prevent tumor-associated
inflammation.
FLP treatment reduces NF-κB expression in tumor tissue
in vivo
NF-κB is activated by inflammatory stimuli and is found
to be constitutively active in several cancers, as a result,
it has long been suspected to be a critical inflammatory
promoter facilitating the initiation and progression of
cancer [21]. NF-κB can induce pro-inflammatory cyto-
kines, such as, IL-6 and TNF-α, and chemokine’s such asry cytokines when co-cultured with THP-1 macrophages. Effect of
IL-6. (A) Representative photomicrographs of A549 cells in matrigel
r CTX, after 48 hours. (B) Image Pro Plus Version 6.0 software was used
en to average migrated cells, all the experiments were repeated 3
es were measure by ELISA data displayed as concentration of (C) TNF-α,
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[22]. We analyzed tumor tissue collected from the Lewis
lung xenograft by immunohistochemistry (Figure 2A)
and western blot (Figure 2B) for NF-κB p65 expression.
We found that FLP treatment can reduce the expression
of NF-κB compared to the PBS vehicle group. Interest-
ingly, CTX treatment was found not to have any effect on
NF-κB expression; however, when CTX is combined with
FLP we found a significant decrease in NF-κB expression.
FLP treatment results in alterations of markers related to
metastatic potential in vivo
Epithelial–Mesenchymal Transition (EMT) plays an im-
portant role in tumor invasion and metastasis [23]. The
major characteristic of EMT is the transformation fromFigure 5 FLP inhibits NF-κB translocation activity and EMT- associated
associated proteins in A549 cells. (A) Western blot analysis of cytoplasmic a
without macrophages, +/− FLP treatment, NRS (vehicle control). (B) Immunof
counterstained with DAPI, representative pictures at original magnification
Slug, ZEB1 expression. (D) Western blot analysis of total protein E-cadherin
total protein MMP2 and MMP9 levels. All the experiments were repeated 3epithelial type cells to more motile, invasive and migratory
mesenchymal type cells [24]. In the process, epithelial cells
lose cell-cell adhesion and cell polarity; In addition, de-
crease the expression of epithelial markers, such as, E-
cadherin, and increase the expression of mesenchymal cell
markers, such as, Vimentin, N-cadherin, alpha smooth
muscle actin (α-SMA) [25]. In addition to EMT, deregula-
tion of the extracellular matrix (ECM) and basement
membrane by matrix metalloproteinase (MMPs), such as,
MMP2, MMP9 is thought to play a key role in cancer cell
invasion and metastasis [26,27]. The presence of macro-
phages and TNF-α secretion can also increase the ex-
pression of MMPs [28,29]. We analyzed the expression
of E-cadherin, N-cadherin, and MMP9 in tumors col-
lected from Lewis lung xenograft mice to measure theprotein in vitro. Effect of FLP on NF-κB expression and EMT-
nd nuclear expression of NF-κB when A549 cells were cultured with or
luorescent staining of NF-κB localization following 24-hour of treatment
× 400 were shown. (C) Western blot analysis of total protein for Snail,
, N-cadherin and Vimentin expression. (E) Western blot analysis of
times.
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and western blot (Figure 2B). As expected, we found al-
tered expression of E-cadherin, N-cadherin, and MMP9 in
PBS treated tumor bearing mice; Interestingly, FLP treat-
ment, as well as, CTX treatment increased E-cadherin ex-
pression and decreased the expression of N-cadherin and
MMP9, with a synergistic effect when FLP and CTX treat-
ment was combined.FLP treatment inhibits cell proliferation in vitro
In order to further evaluate the molecular mechanisms
of FLP anticancer activities, we treated A549 lung car-
cinoma cells, with FLP or CTX treated rat derived serumFigure 6 FLP rescues E-cadherin and inhibits N-cadherin expression in
by immunofluorescence under inflammatory conditions. Photomicrographs o
counterstained with DAPI after pre-treatment with NRS (Vehicle control) or FL
experiments were repeated 3 times.(see cell culture methods). We first evaluated the effects
of FLP treatment on cell proliferation in vitro. Using a
MTT cell proliferation assay we found that FLP treat-
ment could inhibit cell proliferation in A549 cells with
the low dose achieving significant inhibition; however,
not to the same level of inhibition seen with CTX treat-
ment (Figure 3A).
FLP treatment inhibits cell invasion in an in vitro system
of inflammatory microenvironment
Based on the earlier results from the xenograft studies,
we found that inflammation may play a critical role in
establishing the metastatic potential of lung tumors and
that FLP may prevent migration and invasion; in part,vitro. Effects of FLP treatment on E-cadherin and N-cadherin expression
f A549 cells stained with (A) E-cadherin, (B) N-cadherin, respectively
P. Representative pictures at original magnification × 400 were shown. All
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directly test FLP efficacy in preventing invasion, possibly
by modulating inflammation, we co-cultured A549 lung
cancer cells with THP1-macrophages in a cell invasion
assay. We found that a medium dose of FLP treatment
could inhibit lung cancer invasion by 60% (Figure 4A, B).
In addition, we found similar results in a scratch-wound
migration assay (Figure 3B, C). We collected the super-
natant from the co-culture medium at various times
throughout the experiment to measure changes in pro-
inflammatory cytokines. As expected, we found an increase
in pro-inflammatory cytokines TNF-α, IL-6, and IL-1β
when A549 cells are co-cultured withTHP-1 macrophages.
While, FLP treatment could reduce the level of TNF-α at
24 and 48 hours, the levels of IL-6 and IL-1β remainedFigure 7 FLP inhibits MMP2 and MMP9 translocation in vitro. Effects o
immunofluorescence under inflammatory conditions. Photomicrographs of
counterstained with DAPI after pre-treatment with NRS (Vehicle control) or
shown. All experiments were repeated 3 times.unchanged (Figure 4 C, D, and E). We concluded that FLP
inhibition of invasion might be associated with changes in
TNF-α.
FLP treatment inhibits NF-κB activity and nuclear
translocation in vitro
Based on the FLP inhibition of TNF-α concentration de-
scribed above and the proposed role of TNF-α in activat-
ing NF-κB, we examined NF-κB expression in A549 cells
using immunofluorescence. We found that we could in-
duce the nuclear translocation of NF-κB by 16.9 or 13.34
percent by co-culturing A549 cells with THP-1 macro-
phages or with the addition TNF-α, respectively; Interest-
ingly, we found a 11.15 percent decrease in the nuclear
translocation of NF-κB with FLP treatment, compared tof FLP treatment on MMP2 and MMP9 expression by
A549 cells stained with (A) MMP2 (B) MMP9, respectively
FLP. Representative pictures at original magnification × 400 were
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5.93 percent inhibition (Figure 5A, B).FLP treatment reduces the expression of
metastasis- associated proteins in vitro
NF-κB activity has been shown to regulate many down-
stream targets that may be associated with invasion and
metastasis, including, transfer proteins, slug, snail, ZEB1,
and E-cadherin, N-cadherin, and MMP9 as described
above. Our xenograft study, implicated the influence of
FLP treatment on several of the above markers, includ-
ing, E-cadherin, N-cadherin and MMP9. We were able
to support our in vivo findings by western blot showing
that FLP treatment could increase the expression of E-
cadherin and decrease the expression of N-cadherin and
MMP9 (Figure 5D, E) in A549 cells cultured with THP-1
macrophages. In addition, we also found that FLP treat-
ment could decrease the expression of snail, slug, ZEB1,
Vimentin and MMP2, other proteins associated with
metastasis (Figure 5C, D). We show similar results ob-
tained by western blot with immunofluorescence, show-
ing an increase in E-cadherin expression and decreased
N-cadherin levels (Figure 6A, B), as well as, a decrease
in MMP2 and MMP9 expression (Figure 7A, B).Discussion
Reducing tumor-associated inflammation and preventing
reoccurrence and metastasis is an important therapeutic
strategy for the management of lung cancer patients,
and has posed a challenge for the medical community.
Traditional Chinese Medicine offers great potential for
enhancing current treatments for lung cancer, with mini-
mum side effects. Although FLP ointment has been used
to treat lung cancer and prevent lung cancer metastasis
for many years in the clinic in China, the mechanisms
are now being extensively investigated. In this study, we
show that FLP treatment can inhibit tumor growth in a
Lewis lung cancer xenograft study. FLP treatment inhib-
ited tumor growth by approximately 40 percent; and
when combined with chemotherapy drug CTX, inhibited
tumor growth by 83.23 percent. Our results suggest that
FLP treatment could improve the efficiency of chemother-
apeutic drugs for the treatment of lung cancer.
Over the last decade, NF-κB has emerged as major pro-
inflammatory mediator [30,31], and has been implicated
in playing a role in carcinogen-induced lung inflamma-
tion, tumor formation, tumor invasion and metastasis
[32-35]. As a result, many efforts are being made to target
the NF-κB pathway. The predominant mechanism of
NF-κB activation involves phosphorylation, ubiquitination,
and degradation of inhibitors of NF-κB (IκB), allowing
NF-κB dimers to translocate to the nucleus and promote
transcription of target genes [36-38].While the correlation between cancer invasion and
NF-κB activity has been determined the molecular mecha-
nisms is only poorly understood. It is thought that NF-κB
promotes tumor progression, mainly by protecting trans-
formed cells from apoptosis [39]. Some recent reports
suggest that TNF-α is required for EMT and that NF-κB
is essential for this process [40]. We demonstrate that
FLP treatment could inhibit both TNF-α and NF-κB ac-
tivity in vivo and in vitro. In A549 FLP treated cells, we
found a greater inhibition of NF-κB than that seen with
treating A549 cells with a known NF-κB p65 inhibitor,
BAY11-7082. The inhibition of NF-κB by FLP was also
associated with changes in expression of important media-
tors during EMT and invasion [40]. In both in vivo and
in vitro models combining FLP with CTX rescued the al-
tered expression of E-cadherin, N-cadherin and MMP9.
Conclusions
Our results show that FLP ointment is effective in regulat-
ing inflammation within the tumor microenvironment,
through interactions with the NF-κB signaling pathway
and may inhibit lung cancer invasion and metastasis. FLP
treatment combined with conventional therapies may pos-
sibly be used to target other NF-κB activated cancers, such
as, glioblastoma. The current evidence warrant further in-
vestigation, nonetheless, offers promising potential to play
an integral part in the treatment and management of lung
cancer patients.
Abbreviations
FLP: Fei-Liu-Ping ointment; NF-κB: Nuclear factor kappa light chain enhancer
of activated B cells; EMT: Epithelial mesenchymal transition;
CTX: Cyclophosphamide; MMP2: Matrix metalloproteinase 2; MMP9: Matrix
metalloproteinase 9; TNF-α: Tumor necrosis factor alpha; IL-1β: Interleukin-1
beta; IL-6: Interleukin-6.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conceived and designed the experiments: BH WL CC. Performed the
experiments: WL CC LG GZ RL. Analyzed the data: WL CC SS. Contributed
reagents/materials/analysis tools: WL CC LG. Wrote the paper: WL CC SS BH.
All authors read and approved the final manuscript.
Acknowledgments
We thank all the researchers who were involved in this study and we thank
Dr. Matthew R. Young for reviewing and revising this manuscript. We also
thank Xin Qi and Yingxia Pei for technical assistance. We also thank Bingkui
Piao for theory guidance of Chinese Medicine. This study was supported by
the grant from National Natural Science Foundation of China. (No. 81273718;
No. 81102587, No. 2012T50199, No. 20110490559) and from Ministry of Science
and Technology of the People’s Republic of China. (No. 2010ZX09102-216).
Author details
1Oncology Department, Guang’anmen Hospital, China Academy of Chinese
Medical Sciences, Beijing 100053, China. 2Oncology Department, Zhejiang
Provincial Hospital of TCM, Hangzhou, Zhejiang 310006, China. 3Nutritional
Science Research Group, Division of Cancer Prevention, National Cancer
Institute, National Institutes of Health, Rockville, MD 21702, USA. 4Henan
Cancer Hospital affiliated to Zhengzhou University, Zhengzhou, Henan
450003, China.
Li et al. BMC Complementary and Alternative Medicine 2014, 14:153 Page 12 of 12
http://www.biomedcentral.com/1472-6882/14/153Received: 5 October 2013 Accepted: 29 April 2014
Published: 12 May 2014References
1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ:
Cancer statistics, 2005. CA Cancer J Clin 2005, 55(1):10–30.
2. Tang JM, He QY, Guo RX, Chang XJ: Phosphorylated Akt overexpression
and loss of PTEN expression in non-small cell lung cancer confers poor
prognosis. Lung Cancer 2006, 51(2):181–191.
3. Brekken RA, Thorpe PE: Vascular endothelial growth factor and vascular
targeting of solid tumors. Anticancer Res 2001, 21(6B):4221–4229.
4. Xu L, Li H, Xu Z, Wang Z, Liu L, Tian J, Sun J, Zhou L, Yao Y, Jiao L, Su W,
Guo H, Chen P, Liu J: Multi-center randomized double-blind controlled
clinical study of chemotherapy combined with or without traditional
Chinese medicine on quality of life of postoperative non-small cell lung
cancer patients. BMC Complement Altern Med 2012, 12:112.
5. Guo H, Liu JX, Xu L, Madebo T, Baak JP: Traditional Chinese medicine
herbal treatment may have a relevant impact on the prognosis of
patients with stage IV adenocarcinoma of the lung treated with
platinum-based chemotherapy or combined targeted therapy and
chemotherapy. Integr Cancer Ther 2011, 10(2):127–137.
6. Wan C, You S, Quan P, Song Y, Liu T, Lu J, Zheng P: Development and
validation of the quality-of-life assessment system for lung cancer based
on traditional Chinese medicine. Evid Based Complement Altern Med 2012,
2012:945910.
7. Wong R, Sagar CM, Sagar SM: Integration of Chinese medicine into
supportive cancer care: a modern role for an ancient tradition. Cancer
Treat Rev 2001, 27(4):235–246.
8. Yang D, Tian G: Review of experimental study on treatment of lung
cancer with traditional Chinese medicine. Zhongguo Zhong Yao Za Zhi
2009, 34(18):2405–2409.
9. Zhang P, Piao B, Sun G: Influence of feiliuping No. 2 on platelet surface
glycoprotein expression in mid-late stage lung cancer patients.
Zhongguo Zhong Xi Yi Jie He Za Zhi 2000, 20(1):31–33.
10. Zheng HG, Piao BK, Hua BJ: Effect of feiliuping ointment and its
disassembled prescriptions on dendritic cell of mice with transplanted
Lewis lung cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi 2010,
30(12):1288–1291.
11. Coussens LM, Zitvogel L, Palucka AK: Neutralizing tumor-promoting
chronic inflammation: a magic bullet? Science 2013, 339(6117):286–291.
12. Candido J, Hagemann T: Cancer-related inflammation. J Clin Immunol
2013, 33(Suppl 1):S79–84.
13. Bochu W, Liancai Z, Qi C: Primary study on the application of serum
pharmacology in Chinese traditional medicine. Colloids Surf B:
Biointerfaces 2005, 43(3–4):194–197.
14. Cao Y, Zhang D, Zheng G, Zhang J: Study on effect of drug concentration
of "Bushen huayu jiedu fang" drug serum on drug-resistance lung cancer
cells with serum pharmacology. Zhong Yao Cai 2003, 26(4):263–265.
15. Plezia PM, Alberts DS, Peng YM, Xu MJ, Sayers S, Davis TP, Surwit EA,
Meyskens FL Jr: The role of serum and tissue pharmacology studies in
the design and interpretation of chemoprevention trials. Prev Med 1989,
18(5):680–687.
16. Walther H, Meyer FP, Quednow B, Leuschner U, Kohler E, Horenburg I:
Dosage monitoring through measurement of serum level–a task of
clinical pharmacology. Int J Clin Pharmacol Biopharm 1978, 16(8):387–390.
17. Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA,
Miller AH, Payne R, Reuben JM, Wang XS, Lee BN: Are the symptoms of
cancer and cancer treatment due to a shared biologic mechanism? A
cytokine-immunologic model of cancer symptoms. Cancer 2003,
97(11):2919–2925.
18. Lee BN, Dantzer R, Langley KE, Bennett GJ, Dougherty PM, Dunn AJ, Meyers CA,
Miller AH, Payne R, Reuben JM, Wang XS, Cleeland CS: A cytokine-based
neuroimmunologic mechanism of cancer-related symptoms.
Neuroimmunomodulation 2004, 11(5):279–292.
19. Dantzer R: Cytokine-induced sickness behavior: where do we stand?
Brain Behav Immun 2001, 15(1):7–24.
20. Rube CE, Wilfert F, Uthe D, Konig J, Liu L, Schuck A, Willich N, Remberger K,
Rube C: Increased expression of pro-inflammatory cytokines as a cause
of lung toxicity after combined treatment with gemcitabine and thoracic
irradiation. Radiother Oncol 2004, 72(2):231–241.21. Karin M, Cao Y, Greten FR, Li ZW: NF-kappaB in cancer: from innocent
bystander to major culprit. Nat Rev Cancer 2002, 2(4):301–310.
22. Li Q, Verma IM: NF-kappaB regulation in the immune system. Nat Rev
Immunol 2002, 2(10):725–734.
23. Birchmeier W, Birchmeier C: Epithelial-mesenchymal transitions in
development and tumor progression. EXS 1995, 74:1–15.
24. Huber MA, Kraut N, Beug H: Molecular requirements for epithelial-mesenchymal
transition during tumor progression. Curr Opin Cell Biol 2005, 17(5):548–558.
25. Thiery JP, Sleeman JP: Complex networks orchestrate epithelial-mesenchymal
transitions. Nat Rev Mol Cell Biol 2006, 7(2):131–142.
26. Deryugina EI, Quigley JP: Matrix metalloproteinases and tumor metastasis.
Cancer Metastasis Rev 2006, 25(1):9–34.
27. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S: Metastatic
potential correlates with enzymatic degradation of basement membrane
collagen. Nature 1980, 284(5751):67–68.
28. Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, Binder C:
Enhanced invasiveness of breast cancer cell lines upon co-cultivation
with macrophages is due to TNF-alpha dependent up-regulation of
matrix metalloproteases. Carcinogenesis 2004, 25(8):1543–1549.
29. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F,
Pukrop T, Binder C, Balkwill FR: Macrophages induce invasiveness of
epithelial cancer cells via NF-kappa B and JNK. J Immunol 2005,
175(2):1197–1205.
30. Aggarwal BB: Nuclear factor-kappaB: the enemy within. Cancer Cell 2004,
6(3):203–208.
31. Aggarwal BB, Vijayalekshmi RV, Sung B: Targeting inflammatory pathways
for prevention and therapy of cancer: short-term friend, long-term foe.
in Cancer Res 2009, 15(2):425–430.
32. Stathopoulos GT, Sherrill TP, Cheng DS, Scoggins RM, Han W, Polosukhin VV,
Connelly L, Yull FE, Fingleton B, Blackwell TS: Epithelial NF-kappaB activation
promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci U S A
2007, 104(47):18514–18519.
33. Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS,
Fingleton B: Host nuclear factor-kappaB activation potentiates lung
cancer metastasis. Mol Cancer Res 2008, 6(3):364–371.
34. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T:
Requirement for NF-kappaB signalling in a mouse model of lung
adenocarcinoma. Nature 2009, 462(7269):104–107.
35. Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M: Tobacco smoke
promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent
inflammation. Cancer Cell 2010, 17(1):89–97.
36. Karin M, Yamamoto Y, Wang QM: The IKK NF-kappa B system: a treasure
trove for drug development. Nat Rev Drug Discov 2004, 3(1):17–26.
37. Garg A, Aggarwal BB: Nuclear transcription factor-kappaB as a target for
cancer drug development. Leukemia 2002, 16(6):1053–1068.
38. Zhang Y, Chen F: Reactive oxygen species (ROS), troublemakers between
nuclear factor-kappaB (NF-kappaB) and c-Jun NH(2)-terminal kinase
(JNK). Cancer Res 2004, 64(6):1902–1905.
39. Karin M, Lin A: NF-kappaB at the crossroads of life and death. Nat Immunol
2002, 3(3):221–227.
40. Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK,
Ding Q, Wang Y, Lai YJ, LaBaff AM, Wu TJ, Lin BR, Yang MH, Hortobagyi GN,
Hung MC: Epithelial-mesenchymal transition induced by TNF-alpha requires
NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res
2012, 72(5):1290–1300.
doi:10.1186/1472-6882-14-153
Cite this article as: Li et al.: Fei-Liu-Ping ointment inhibits lung cancer
growth and invasion by suppressing tumor inflammatory
microenvironment. BMC Complementary and Alternative Medicine
2014 14:153.
